Unit Vaccinology, National Institute for Public Health and the Environment (RIVM), A. van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
Eur J Pharm Sci. 2012 May 12;46(1-2):1-7. doi: 10.1016/j.ejps.2012.01.013. Epub 2012 Feb 4.
In the search for an optimal approach for the transcutaneous immunization (TCI) of hepatitis B surface antigen (HBsAg), two vesicle formulations, L595 vesicles (composed of sucrose-laurate ester and octaoxyethylene-laurate ester) and sPC vesicles (composed of soybean-phosphatidylcholine and Span-80) were prepared and characterized in vitro and in vivo. HBsAg was associated to the vesicles, resulting in sPC-HBsAg vesicles (±170nm) with 79% HBsAg association and L595-HBsAg vesicles (±75nm) with only 29% HBsAg association. The vesicles induced in mice via TCI an antibody response only when the skin was pretreated with microneedles. This response was improved by the adjuvant cholera toxin. The sPC-HBsAg vesicle formulations showed to be the most immunogenic for TCI, which was related to the higher degree of HBsAg association.
为了寻找乙肝表面抗原(HBsAg)经皮免疫接种(TCI)的最佳方法,我们制备并体外和体内鉴定了两种囊泡制剂,L595 囊泡(由蔗糖月桂酸酯和辛氧乙烯月桂酸酯组成)和 sPC 囊泡(由大豆磷脂酰胆碱和司盘 80 组成)。HBsAg 与囊泡结合,得到 sPC-HBsAg 囊泡(±170nm),HBsAg 结合率为 79%,L595-HBsAg 囊泡(±75nm)结合率仅为 29%。只有当皮肤用微针预处理时,囊泡才能通过 TCI 在小鼠体内引发抗体反应。霍乱毒素佐剂可提高这种反应。sPC-HBsAg 囊泡制剂在 TCI 中显示出最高的免疫原性,这与 HBsAg 结合程度较高有关。